Lobbying client · LD-2 disclosures
Elevar Therapeutics
New Jersey
4 filings from 1 registrant · 2024 · latest filed Jan 21, 2025
Reported on its behalf
$100K
every LD-2 on file
Its own filed spend
$0
lobbying for itself
Fees to outside firms
$100K
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Pharmacy
PHA
4 filings
$100K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
Who did the lobbying
Every lobbyist named on this client's filings.
- Liesl Grebenstein Sheehan Tremont Strategies Group LLC (F/K/A Ads Ventures)5 filingsthrough 2024
The filings
Every filing on record. Each row links to its full disclosure.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: elevar-therapeutics.